Swiss Cancer Institute/BMS Grant "HEM Pioneer"
Many types of blood cancer remain incurable and are associated with severe morbidity and increased mortality. The Swiss Cancer Institute/BMS Grant "HEM Pioneer" is funded by BMS and supports projects that can pave the way for a fundamental change in the treatment of blood cancer. The prize is endowed with CHF 20'000.–.
Applicants
- You are a practicing physician, active in clinical research or a specialist in a care facility
- Carry out your research activities mainly in Switzerland
- Must finance your project via a company account
Your project
- Aims to pave the way for a potentially groundbreaking impact in the field of hemato-oncological diseases and their precursors
- Has a research character (e.g. clinical or translational research, research with databases/registries, work and patient care models, quality of life tools)
- Must not be concerned with basic research
- May focus on aspects such as treatment approaches, mode of action of drugs, type of disease, interdisciplinary communication/collaboration, etc.
- Is carried out in Switzerland
- Is planned or already underway
Application
Your application must:
- Be written in English and include the following information:
- Project title, rationale/background, aim of the project and the potential significant impact on the type of blood cancer being studied
- Detailed description of the project with project plan and methodology including statistical methods (if applicable), timeframe/duration of the project and budget
- CVs of all applicants
Applications that do not meet all of the above requirements cannot be considered.
Submission
Please submit your application by March 31, 2025.
Applications must be submitted electronically to the Swiss Cancer Institute, events@swisscancerinstitute.ch.
In cooperation with BMS.